Case Study on Moderna Published by Harvard Business School:
— Brook Jackson 💜 (@IamBrookJackson) January 22, 2023
"The level of reckless disregard for product safety, rational drug design, rigorous testing and quality control in biologics manufacturing is astounding." – Sasha Latypova https://t.co/No4l9lwTyt
Ominous conversational harbinger for the looming holidays
https://bsky.app/profile/technologyreview.com/post/3m5jfmkihhk2z
